Grant History

The $5.1M of total grant support we've given to funding research is made possible by the generosity of our sponsors and donors. Real people making an impact on saving children's eyesight.

Grant Amount

$3M
2024
$2.1M

2025

Year
Grant Amount
Month
Amount/ month
Purpose

2026

$1.1M

January
$1.1M

To close the remaining funding gap required to launch the AXV-101 clinical trial, enabling the study to begin in early 2026.

2025

$1M

September
$1M

To support clinical development of the first-in-human trial, including trial preparation and regulatory progress following clinical trial clearance.

2024

$3M

October
$1M
December
$2M

To fund the preclinical development and regulatory preparation of AXV-101, a gene therapy for Bardet-Biedl Syndrome type 1 (BBS1), advancing the program toward its first human clinical trial.

News and Articles

Recent News
January 06, 2026
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

Newly added funding closes critical gap and enables planned trial initiation in early 2026

Read More
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

Latest Posts

August 15, 2025
Hope on the Horizon: Breakthrough Phase 2 Results for Stargardt Disease Therapy

A groundbreaking Phase 2 trial has shown the first-ever vision improvements in people with Stargardt disease — a condition with no approved treatment. Nanoscope Therapeutics’ gene-agnostic MCO-010 therapy produced meaningful gains in vision without serious side effects, paving the way for a pivotal Phase 3 trial starting in 2025.

Read More
March 25, 2025
Global Experts Advancing Bardet-Biedl Syndrome Research
Read More